HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Tyra Biosciences and raised the price target from $25 to $30, indicating confidence in the company's future performance.
October 07, 2024 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has increased its price target for Tyra Biosciences from $25 to $30, maintaining a Buy rating. This suggests a positive outlook for the company's stock.
The increase in price target from $25 to $30 by HC Wainwright & Co. reflects a positive sentiment and confidence in Tyra Biosciences' future performance. This is likely to have a positive short-term impact on the stock price as investors may view the raised target as a sign of potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100